Skip to main content

Day: October 17, 2021

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observed The totality of evidence from VALOR and its ongoing open-label extension showed that participants who started tofersen earlier experienced better outcomes, further suggesting a positive clinical effect Topline data being presented today at the American Neurological Association 2021 Annual Meeting Given the high unmet medical need, Biogen will expand its ongoing early access program (EAP) to the broader SOD1-ALS populationA Media Snippet accompanying this announcement is available by clicking on the image or link below:CAMBRIDGE, Mass., Oct. 17,...

Continue reading

68 MW wind power agreement has been terminated by Commerz Real

Hässleholm, Sweden, October 17th, 2021 On September 29th, 2020, Eolus announced the sale of three wind farms in Sweden with an installed capacity of 68 MW. Eolus has been notified that the investor Commerz Real has terminated the share purchase agreement due to conditions for the transaction not being fulfilled. As a consequence of the terminated agreement Eolus’ order backlog will decrease with the amount of EUR 82.5 million and signed contracts for future asset management services will decrease by 68 MW. No revenues from the agreement have been recognized in Eolus’ financial reports. Eolus will pay a termination fee of 200,000 EUR to the investor Commerz Real. Conditions not fulfilled relates to sufficient permits not being granted by the authorities before the long-stop date in the agreement between Eolus and Commerz Real. Eolus will...

Continue reading

Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs

VANCOUVER, British Columbia, Oct. 16, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (FWB: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, congratulates Seattle’s city council in their unanimous vote to decriminalize the use, possession and cultivation of naturally occurring entheogenic drugs, including psilocybin for “religious, spiritual, healing or personal growth practices.” On Monday, October 4, 2021, the City of Seattle officially became the largest city in the United States to decriminalize non-commercial use around a number of psychedelic substances that originate from “living, fresh, dried or processed plant or fungal material, including...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.